74171-22-5

Basic information

• Product Name: 2,4-dioxo-1H-3,1-benzoxazine-6-sulfonyl chloride
• Synonyms: 2,4-dioxo-1H-3,1-benzoxazine-6-sulfonyl chloride
• CAS NO: 74171-22-5
• Molecular Weight: 261.642
• Mol File: 74171-22-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2,4-dioxo-1H-3,1-benzoxazine-6-sulfonyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-dioxo-1H-3,1-benzoxazine-6-sulfonyl chloride(74171-22-5)
• EPA Substance Registry System: 2,4-dioxo-1H-3,1-benzoxazine-6-sulfonyl chloride(74171-22-5)

Safety Data

• Hazardous Substances Data: 74171-22-5(Hazardous Substances Data)

Usage

General Description

2,4-dioxo-1H-3,1-benzoxazine-6-sulfonyl chloride, also known as Benzoxazinone-6-sulfonyl chloride, is a chemical compound with the molecular formula C13H7ClN2O5S. It is a white to off-white crystalline powder and is primarily used as a reagent for the synthesis of benzoxazinones, which are important building blocks in medicinal chemistry. Benzoxazinone-6-sulfonyl chloride is a versatile reagent that can be used in the preparation of a wide range of pharmaceutical compounds through various synthetic methods. It is also used as a coupling reagent in peptide synthesis and as a protecting group for amino acids. Additionally, this compound is utilized in the development of new chemical entities for drug discovery and development due to its unique chemical and biological properties.

Upstream product

• 118-48-9 isatoic anhydride 

Downstream Products

• 1945950-21-9 PDD00017273 

Relevant articles and documents

Cell-Active Small Molecule Inhibitors of the DNA-Damage Repair Enzyme Poly(ADP-ribose) Glycohydrolase (PARG): Discovery and Optimization of Orally Bioavailable Quinazolinedione Sulfonamides

DNA damage repair enzymes are promising targets in the development of new therapeutic agents for a wide range of cancers and potentially other diseases. The enzyme poly(ADP-ribose) glycohydrolase (PARG) plays a pivotal role in the regulation of DNA repair mechanisms; however, the lack of potent drug-like inhibitors for use in cellular and in vivo models has limited the investigation of its potential as a novel therapeutic target. Using the crystal structure of human PARG in complex with the weakly active and cytotoxic anthraquinone 8a, novel quinazolinedione sulfonamides PARG inhibitors have been identified by means of structure-based virtual screening and library design. 1-Oxetan-3-ylmethyl derivatives 33d and 35d were selected for preliminary investigations in vivo. X-ray crystal structures help rationalize the observed structure-activity relationships of these novel inhibitors.

BRADYKININ RECEPTOR ANTAGONISTS

The invention relates to sulfonyl amine derivatives of formula IA wherein R5A, X1, X2, R9 and R10 are as defined herein, which derivatives are useful as bradykinin B1 receptor antagonists.